This retrospective study published in the Journal of Clinical Oncology looked at the response rates and progression-free survival of metastatic renal cell carcinoma (RCC) patients treated with a combination of ipilimumab plus nivolumab after previous treatment with an immune checkpoint inhibitor.
Forty-five patients with metastatic RCC who had already been treated with an immune checkpoint inhibitor followed by a combination of ipilimumab plus nivolumab were included in the study. The objective response rate was 20%, and the median progression-free survival was 4 months.
The combination of ipilimumab and nivolumab after treatment with an immune checkpoint inhibitor is effective in these patients, but prospective data are needed to confirm the results.
